US kidney care speciailst Evergreen Nephrology announced on Tuesday the appointment of David Young to its board of directors.
Young has served in leadership roles such as CEO of GenesisCare, president & CEO of Physicians Endoscopy Inc and COO of Privia Health Inc. He has also worked in senior-level positions at Smile Brands Inc McKesson Specialty Health and US Oncology Inc.
Young will continue to serve on the boards of GenesisCare Cayman Holdings, GenesisCare UK Ltd and Biocartis Holdings Inc.
Adam Boehler, Evergreen Nephrology executive chairman, said: "Evergreen is at an exciting point in its growth, forming new partnerships with nephrologists nationwide, aligning with new payors, and pioneering cutting-edge research. David's extensive operational, financial and executive leadership in healthcare will be invaluable as we pursue our work of providing exceptional kidney care tailored to each patient's journey."
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial
Turnstone Biologics announces strategic restructuring
Pfizer's TALZENNA plus XTANDI shows promise in prostate cancer treatment
GenesisCare UK selects RayStation for radiotherapy system upgrade
Boehringer Ingelheim and Circle Pharma collaborate on cancer treatment
Petauri launches medical communications platform Petauri Advance
Bayer and MOMA Therapeutics enter oncology collaboration
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
MediLink enters clinical trial collaboration and supply agreement with Amgen